scholarly journals Convergent Validity of the Dutch Central Sensitization Inventory: Associations with Psychophysical Pain Measures, Quality of Life, Disability, and Pain Cognitions in Patients with Chronic Spinal Pain

Pain Practice ◽  
2018 ◽  
Vol 18 (6) ◽  
pp. 777-787 ◽  
Author(s):  
Jeroen Kregel ◽  
Charline Schumacher ◽  
Mieke Dolphens ◽  
Anneleen Malfliet ◽  
Dorien Goubert ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Central Sensitization ◽  
Convergent Validity ◽  
Spinal Pain ◽  
Pain Cognitions ◽  
Central Sensitization Inventory ◽  
Chronic Spinal Pain

scholarly journals Psychometric validation of the Polish version of the Central Sensitization Inventory in subjects with chronic spinal pain

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Barbara Kosińska ◽  
Beata Tarnacka ◽  
Paweł Turczyn ◽  
Grażyna Gromadzka ◽  
Małgorzata Malec-Milewska ◽  
...  
Keyword(s):  
Internal Consistency ◽  
Central Sensitization ◽  
Spinal Pain ◽  
Retest Reliability ◽  
Control Subjects ◽  
Polish Version ◽  
Healthy Control ◽  
Central Sensitization Inventory ◽  
Test Retest Reliability ◽  
Chronic Spinal Pain

Abstract Background Central sensitization is an amplification of neuronal signaling within the central nervous system. The Central Sensitization Inventory was introduced in 2012. A Polish version of the CSI (CSI-Pol) was developed in 2019, but it was not psychometrically validated. The aim of this study was to validate the CSI-Pol in a sample of Polish-speaking patients with chronic spinal pain and compare them with a group of healthy control subjects. Methods The CSI-Pol was administered to 151 patients with chronic spinal pain recruited from two centers. It was re-administered 7 days later. The psychometric properties were then evaluated, including test-retest reliability, construct validity, factor structure and internal consistency. We correlated the CSI-Pol with functional scales, depression and social support scales and compared CSI-Pol scores in the clinical subjects with 30 healthy control subjects recruited from medical staff and their families. Results The CSI-Pol demonstrated excellent internal consistency (Cronbach’s α =0,933) and test-retest reliability (Intraclass Correlation Coefficients - ICC =0.96), as well as significant positive associations with other patient-reported scales, including the Neck Disability Index (r = 0.593), Revised Oswestry Low Back Pain Disability Questionnaire (r = 0.422), and other measures of functional and depressive states. An exploratory factor analysis resulted in a 4-factor model. CSI-Pol scores in the clinical sample (35.27 ± 17.25) were significantly higher than the control sample (23.3 ± 8.9). Conclusion The results of this study suggest that the CSI-Pol may be a useful clinical tool for assessing central sensitization related symptoms and guiding appropriate treatment in Polish-speaking patients with spinal pain.

scholarly journals The quality of life of patients with chronic pain, hospitalized in conservative treatment wards

2016 ◽  
Vol 15 (4) ◽  
pp. 18-27
Author(s):  
Olga Bielan ◽  
Julia Gutowska ◽  
Mariola Ejdys
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Pain Intensity ◽  
Disease Process ◽  
Pain Syndrome ◽  
Spinal Pain ◽  
Epidemiological Studies ◽  
The Impact ◽  
Chronic Spinal Pain

Abstract Introduction. Pain is one of the most frequent human ailment. Not not only is it the first and often the only symptom of ongoing disease process, but also a warning of impending danger. According to the European epidemiological studies, it is estimated that chronic pain occurs in 19% of the population. This means that within a year this condition is diagnosed in 7 million patients in Poland. Treatment of chronic pain is complicated due to the variety of its origin.Aim. Influence of chronic pain in hospitalized patients on their daily quality of life.Material and methods. The study included 80 patients with a chronic spinal pain syndrome. To evaluate the intensity of pain, the numerical scale (NRS), the verbal scale (VRS) and the abbreviated version of the McGill Questionnaire were used. To measure the quality of life, the SF-36 was used.Results. The results of analysis of the collected material confirmed the impact of chronic pain on the quality of life of the hospitalized. Assessment of pain intensity decreased in the group of patients after one week of treatment. On the other hand, in assessing the overall perception of health, quality of life and its various dimensions, a difference between the two groups and the different stages of the study was observed. Own study confirms the equivalence of psychosocial factors modulating the level of pain and the quality of life.Conclusions. There is a relationship between pain intensity and the level of quality of life as well as its individual components before and after the treatment in patients with chronic spinal pain. Some significant changes between the variables were separated in the accepted stages of the study among people with chronic pain.

scholarly journals Validity and reliability of the Turkish version of the central sensitization inventory

2021 ◽  
Vol 36 (4) ◽  
pp. 518-526
Author(s):  
Ela Düzce Keleş ◽  
Murat Birtane ◽  
Galip Ekuklu ◽  
Cumhur Kılınçer ◽  
Okan Çalıyurt ◽  
...  
Keyword(s):  
Internal Consistency ◽  
Central Sensitization ◽  
Intraclass Correlation ◽  
Spinal Pain ◽  
Psychometric Validation ◽  
Healthy Controls ◽  
Retest Reliability ◽  
Central Sensitization Inventory ◽  
Test Retest Reliability ◽  
Chronic Spinal Pain

Objectives: The aim of this study was to translate the Central Sensitization Inventory (CSI) into the Turkish language, to perform a psychometric validation, and to investigate its reliability in patients with chronic spinal pain with an organic origin, patients with fibromyalgia, and pain-free control individuals. Patients and methods: Between April 2016 and February 2017, the translation of the original English version of the CSI into Turkish was performed using the forward-backward translation method. A total of 100 fibromyalgia patients (6 males, 94 females; mean age: 45.0±8.4 years; range, 25 to 60 years), 100 patients with chronic spinal pain with an identified organic origin (CSPO), (10 males, 90 females; mean age: 43.8±9.7 years; range, 21 to 60 years), and 100 healthy controls (8 males, 92 females; mean age: 35.8±10.1 years; range, 25 to 55 years) were included in the study. Demographic characteristics were collected. Test-retest reliability was determined by re-administering the CSI-Turkish (CSI-Turk) two weeks after the first application. Results: The internal consistency (Cronbach's alpha) was found to be 0.92 and the intraclass correlation coefficient was 0.93. Patients with fibromyalgia, a very common central sensitivity syndrome (CSS), had the highest mean CSI-Turk scores, and healthy controls had the lowest. Using the recommended cut-off score of 40 resulted in 87% sensitivity and 90% specificity in distinguishing between fibromyalgia and control individuals. Conclusion: This study suggests that the CSI-Turk can be effectively used as a screening tool to elucidate CS-related symptomology among patients with chronic pain with a high internal consistency, test-retest reliability, sensitivity, and specificity.

Translation and Validation of the Thai Version of the Wisconsin Quality of Life Questionnaire (TH WISQoL) for Kidney Stone Patients

2020 ◽  
Vol 103 (11) ◽  
pp. 1194-1199
Keyword(s):  
Quality Of Life ◽  
Internal Consistency ◽  
Kidney Stone ◽  
Convergent Validity ◽  
Large Scale ◽  
Short Form ◽  
Outcome Measurement ◽  
Life Questionnaire ◽  
Sf 36

Objective: To develop and validate a Thai version of the Wisconsin Quality of Life (TH WISQoL) Questionnaire. Materials and Methods: The authors developed the TH WISQoL Questionnaire based on a standard multi-step process. Subsequently, the authors recruited patients with kidney stone and requested them to complete the TH WISQoL and a validated Thai version of the 36-Item Short Form Survey (TH SF-36). The authors calculated the internal consistency and interdomain correlation of TH WISQoL and compared the convergent validity between the two instruments. Results: Thirty kidney stone patients completed the TH WISQoL and the TH SF-36. The TH WISQoL showed acceptable internal consistency for all domains (Cronbach’s alpha 0.768 to 0.909). Interdomain correlation was high for most domains (r=0.698 to 0.779), except for the correlation between Vitality and Disease domains, which showed a moderate correlation (r=0.575). For convergent validity, TH WISQoL demonstrated a good overall correlation to TH SF-36, (r=0.796, p<0.05). Conclusion: The TH WISQoL is valid and reliable for evaluating the quality of life of Thai patients with kidney stone. A further large-scale multi-center study is warranted to confirm its applicability in Thailand. Keywords: Quality of life, Kidney stone, Validation, Outcome measurement

scholarly journals POS0919 BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 720.2-721
Author(s):  
X. Baraliakos ◽  
M. Dougados ◽  
K. Gaffney ◽  
R. Sengupta ◽  
M. Magrey ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ankylosing Spondylitis ◽  
Patient Reported Outcomes ◽  
Morning Stiffness ◽  
Spinal Pain ◽  
Research Support ◽  
Sf 36 ◽  
Patient Reported ◽  
Full Analysis

Background:Bimekizumab (BKZ), a monoclonal antibody that selectively inhibits interleukin (IL)-17A and IL-17F, has demonstrated clinical efficacy and safety in patients with ankylosing spondylitis (AS) treated over a period up to 96 weeks.1,2Objectives:To report 3-year interim patient-reported outcomes (PROs) in patients with active AS treated with BKZ in a phase 2b dose-ranging study (BE AGILE; NCT02963506) and its open-label extension (OLE; NCT03355573).Methods:BE AGILE study design has been described previously.1 Patients treated with BKZ 160 mg or 320 mg every 4 weeks (Q4W) at Week 48 in BE AGILE were eligible for OLE entry. All OLE patients received BKZ 160 mg Q4W. Outcome measures are reported for the OLE full analysis set (patients who entered the OLE and had ≥1 dose of BKZ and ≥1 valid efficacy variable measurement in the OLE), and include: BASDAI, BASDAI50 responder rate, BASFI, fatigue (BASDAI Q1), morning stiffness (mean of BASDAI Q5 + 6), total spinal pain (numeric rating scale [NRS]), SF-36 PCS and MCS, and ASQoL. Missing data were imputed using multiple imputation (MI; based on the missing at random assumption) for continuous variables and non-responder imputation (NRI) for dichotomous variables.Results:262/303 (86%) patients randomised at BE AGILE study baseline (BL) completed Week 48 on BKZ 160 mg or 320 mg, of whom 255/262 (97%) entered the OLE (full analysis set: 254). From baseline to Week 48 in BE AGILE, BKZ-treated patients showed clinically relevant improvements in disease activity (BASDAI, BASDAI50), physical function (BASFI), fatigue, morning stiffness, spinal pain, and quality of life (SF-36 PCS and MCS, ASQoL) (Figure 1). Group-level improvements in all reported continuous efficacy measures exceeded published minimally important difference (MID), minimum clinically important improvement (MCII), and/or minimum clinically important difference (MCID) thresholds (Figure 1).3,4 Efficacy in all reported outcome measures was maintained or continued to improve from Week 48 to Week 144 or 156 (Figure 1).Conclusion:BKZ treatment was associated with sustained and consistent efficacy in patients with active AS over 3 years, including patient-reported disease activity, physical function, fatigue, morning stiffness, spinal pain, and quality of life.References:[1]van der Heijde D. Ann Rheum Dis 2020;79:595–604.[2]Baraliakos X. Arthritis Rheumatol 2020;72 (suppl 10).[3]Ogdie A. Arthritis Care Res 2020;72 (S10):47–71.[4]Maruish ME. User’s manual for the SF-36v2 Health Survey (3rd ed). 2011; Lincoln, RI: QualityMetric Incorporated.Acknowledgements:This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.Disclosure of Interests:Xenofon Baraliakos Speakers bureau: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, UCB Pharma, Paid instructor for: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, UCB Pharma, Maxime Dougados Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer and UCB Pharma, Grant/research support from: AbbVie, Eli Lilly, Novartis, Pfizer and UCB Pharma, Karl Gaffney Speakers bureau: AbbVie, Eli Lilly, Novartis, UCB Pharma, Consultant of: AbbVie, Eli Lilly, Novartis, UCB Pharma, Grant/research support from: AbbVie, Gilead, Eli Lilly, Novartis, UCB Pharma, Raj Sengupta Speakers bureau: AbbVie, Biogen, Celgene, MSD, Novartis, UCB Pharma, Consultant of: AbbVie, Biogen, Celgene, Eli Lilly, MSD, Novartis, UCB Pharma, Grant/research support from: AbbVie, Celgene, UCB Pharma, Marina Magrey Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie, UCB Pharma, Natasha de Peyrecave Employee of: UCB Pharma, Marga Oortgiesen Employee of: UCB Pharma, Thomas Vaux Employee of: UCB Pharma, Carmen Fleurinck Employee of: UCB Pharma, Valerie Ciaravino Employee of: UCB Pharma, Atul Deodhar Speakers bureau: Janssen, Novartis, Pfizer, Consultant of: AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB Pharma

Translation and initial validation of the occupational balance questionnaire to Arabic—Occupational Balance Questionnaire-A

2021 ◽  
pp. 030802262110394
Author(s):  
Brightlin N Dhas ◽  
Petra Wagman ◽  
Firas A Marji ◽  
Carita Håkansson ◽  
Ricardo Carrasco
Keyword(s):  
Quality Of Life ◽  
Internal Consistency ◽  
Content Validity ◽  
Convergent Validity ◽  
Occupational Therapists ◽  
Health Indicators ◽  
Family Quality Of Life ◽  
Cognitive Debriefing ◽  
Arabic Speaking

Introduction Occupational balance (OB) is related to many health indicators, including quality of life. The Occupational Balance Questionnaire (OBQ11) was developed to measure OB, and to date, no Arabic translations of the questionnaire exist. The aim of the study was to describe the translation process of OBQ11 to Arabic and to evaluate its content validity, internal consistency, construct validity, and convergent validity. Methods OBQ11 was translated to Arabic (OBQ11-A) following standard guidelines. Content validity feedback was obtained from ten Arabic-speaking occupational therapists and in a cognitive debriefing with seven volunteers. In addition, OBQ11-A and the Family Quality of Life Survey-2006 were administered to 67 Arabic-speaking participants from a larger study about OB among parents. Results High level of agreement was found on the content of OBQ11-A from the occupational therapists. Cognitive debriefing interviews indicated that OBQ11-A was easy to understand. Cronbach’s alpha for the total OBQ11-A score was 0.864 indicating good internal consistency. Exploratory factor analysis showed acceptable factor loadings for all items. The total scores showed positive statistically significant associations with Family Quality of Life Scores ( r = 0.561, p < 0.001). Conclusions OBQ11-A may prove useful for assessing OB in Arabic-speaking populations. Further research is needed to establish its reliability.

scholarly journals Translation, adaptation and initial validation of Food Allergy Quality of Life Questionnaire: child form in Greek

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Zoe Morou ◽  
Georgios N. Lyrakos ◽  
Nikolaos G. Papadopoulos ◽  
Nikolaos Douladiris ◽  
Athina Tatsioni ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Factor Analysis ◽  
Food Allergy ◽  
Convergent Validity ◽  
Underlying Structure ◽  
Life Questionnaire ◽  
Cronbach’S Alpha ◽  
Quality Of Life Questionnaire ◽  
Cronbach's Alpha

The aim of the study is to determine the reliability and validity of the Greek version of the Food Allergy Quality of life Questionnaire- Child Form (FAQLQ-CF). After linguistic validation, the Greek FAQLQCF, Food Allergy Independent Measure (FAIM) and Pediatric Quality of Life Inventory (PedsQL™) were used by a physician to interview children diagnosed with food allergy and aged 8-12 via telephone. Cronbach’s alpha was used to evaluate reliability, and factor analysis to assess construct validity. The correlation between FAQLQ-CF and FAIM was moderate (rho=0.509, P&lt;0.001) and internal consistency was strong (Cronbach’s alpha 0.905). FAQLQ-CF discriminated well each question’s contribution to children’s quality of life deterioration (32- 80%), each child’s quality of life (17-89%), children differing in doing things with others (total score 3.55 vs 2.57, difference =0.98 &gt; minimal clinical importance difference = 0.5; P&lt;0.001), but not children differing in reporting anaphylaxis. The total FAQLQ-CF score correlated with the total PedsQL™ score and with the score of one of PedsQL™ subscales, demonstrating convergent validity. Factor analysis uncovered an underlying structure of four factors, explaining 50% of the variance. We can conclude that Greek FAQLQ-CF is a reliable, valid, discriminant tool for interviewing food allergic children aged 8- 12, detecting those in need for immediate care.

Sign in / Sign up

Export Citation Format

Share Document